These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28692169)

  • 1. The relationship between anxiety and quality of life in children with hereditary angioedema.
    Kessel A; Farkas H; Kivity S; Veszeli N; Kőhalmi KV; Engel-Yeger B
    Pediatr Allergy Immunol; 2017 Nov; 28(7):692-698. PubMed ID: 28692169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life among children with hereditary angioedema.
    Engel-Yeger B; Farkas H; Kivity S; Veszeli N; Kőhalmi KV; Kessel A
    Pediatr Allergy Immunol; 2017 Jun; 28(4):370-376. PubMed ID: 28258590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in Danish children with hereditary angioedema.
    Aabom A; Nguyen D; Fisker N; Bygum A
    Allergy Asthma Proc; 2017 Nov; 38(6):440-446. PubMed ID: 29046193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study.
    Savarese L; Bova M; De Falco R; Guarino MD; De Luca Picione R; Petraroli A; Senter R; Traverso C; Zabotto M; Zanichelli A; Zito E; Alessio M; Cancian M; Cicardi M; Franzese A; Perricone R; Marone G; Valerio P; Freda MF
    Orphanet J Rare Dis; 2018 Jul; 13(1):115. PubMed ID: 30005674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency.
    Suffritti C; Zanichelli A; Maggioni L; Bonanni E; Cugno M; Cicardi M
    Clin Exp Allergy; 2014 Dec; 44(12):1503-14. PubMed ID: 24552232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema.
    Loffredo S; Bova M; Suffritti C; Borriello F; Zanichelli A; Petraroli A; Varricchi G; Triggiani M; Cicardi M; Marone G
    Allergy; 2016 Jul; 71(7):989-96. PubMed ID: 26873113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL.
    Prior N; Remor E; Pérez-Fernández E; Caminoa M; Gómez-Traseira C; Gayá F; Aabom A; Aberer W; Betschel S; Boccon-Gibod I; Bouillet L; Bygum A; Csuka D; Farkas H; Gomide M; Grumach A; Leibovich I; Malbran A; Moldovan D; Mihaly E; Obtulowicz K; Perpén C; Peveling-Oberhag A; Porebski G; Chavannes CR; Reshef A; Staubach P; Wiednig M; Caballero T
    J Allergy Clin Immunol Pract; 2016; 4(3):464-473.e4. PubMed ID: 26969268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.
    Kőhalmi KV; Veszeli N; Cervenak L; Varga L; Farkas H
    Immunol Lett; 2017 Sep; 189():90-93. PubMed ID: 28577900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study.
    Anderson J; Soteres D; Mellor J; Connolly H; Wynne-Cattanach K; Earl L; Schultz BG; Juethner S
    Allergy Asthma Proc; 2024 Jul; 45(4):247-254. PubMed ID: 38982603
    [No Abstract]   [Full Text] [Related]  

  • 13. C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.
    Bewtra AK; Levy RJ; Jacobson KW; Wasserman RL; Machnig T; Craig TJ
    Allergy Asthma Proc; 2012; 33(5):427-31. PubMed ID: 23026185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1.
    Kajdácsi E; Jani PK; Csuka D; Varga L; Prohászka Z; Farkas H; Cervenak L
    J Clin Immunol; 2016 Feb; 36(2):160-70. PubMed ID: 26873707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency.
    Zotter Z; Nagy Z; Patócs A; Csuka D; Veszeli N; Kőhalmi KV; Farkas H
    Orphanet J Rare Dis; 2017 Jan; 12(1):5. PubMed ID: 28069032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary angioedema due to C1-inhibitor deficiency in Macedonia: clinical characteristics, novel SERPING1 mutations and genetic factors modifying the clinical phenotype.
    Grivčeva-Panovska V; Košnik M; Korošec P; Andrejević S; Karadža-Lapić L; Rijavec M
    Ann Med; 2018 May; 50(3):269-276. PubMed ID: 29513108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
    Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
    Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychological processes in the experience of hereditary angioedema in adult patients: an observational study.
    Savarese L; Bova M; Maiello A; Petraroli A; Mormile I; Cancian M; Senter R; Zanichelli A; Spadaro G; Freda MF
    Orphanet J Rare Dis; 2021 Jan; 16(1):23. PubMed ID: 33422102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.
    Farkas H; Kőhalmi KV; Visy B; Veszeli N; Varga L
    J Allergy Clin Immunol Pract; 2020; 8(7):2379-2383. PubMed ID: 32198128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks.
    Lumry WR; Miller DP; Newcomer S; Fitts D; Dayno J
    Allergy Asthma Proc; 2014; 35(5):371-6. PubMed ID: 25295804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.